DISCOVER OUR BOARD MEMBERS.
DISCOVER OUR BOARD MEMBERS.
lino Biotech AG was founded in 2020.
With the support of Hoffman-La Roche AG, we are bringing the benefits of focal molography to the drug discovery market. We are happy to introduce our board members, bringing together numerous years of experience in building life science companies, as well as licensing deals and investment strategies.
Monique Schiersing
Monique is a Senior Investment Director at the Roche Venture Fund. Former roles include serving as the Chief Operating Officer at Inthera Bioscience AG, a previous Director position at Roche Venture Fund from 2009 to 2018, and a principal position with BankInvest’s BioMedical Ventures Group in Copenhagen.
In addition, Monique’s background includes several years in Roche’s Pharma business development group, and various other positions in academia, biotech and venture capital, both in Switzerland and the San Francisco Bay Area. Monique holds a M.Sc. in microbiology from the University of Zurich (Switzerland) and an MBA from the University of San Francisco.
Dr. Robert Wicke
Seppo Mäkinen
Dr. Mirko Stange
Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and research tool expert driven by the goal to support the development and successful commercialization of life science innovations. He has extensive founder and executive management experience in taking companies from start to success exit. Following completing his Ph.D. in Biochemistry & Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey and subsequently worked with the turn-around specialist Droege & Comp., serving mainly clients from the pharma and chemistry industry in Germany and Switzerland. In 2008 he founded an independent Life Sciences consultancy in Germany where, to date, a team of international experts identify, fund and build innovative business opportunities. To date, three co-founded companies were successfully exited. Dr. Stange is also named investor on several granted and pending patents.
Dr. Matthias Essenpreis
Matthias Essenpreis, Chief Technology Officer at Roche Diagnostics, has been with Roche Diagnostics since 1993 and has held various positions in technology assessment, research and product development. In his role as CTO, he leads a team to assess platform technologies for future diagnostics products and provides input for business and strategy planning with insights on technology roadmaps. Matthias holds a PhD in Medical Physics from University College London, U.K. and received his M.Sc. Degree in Physics from Ludwig Maximilians Universität in Munich, Germany.
